pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium
September 03 2015 - 8:00AM
Business Wire
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the
development of sustained release drug delivery products for
treating eye diseases, today announced Dr. Paul Ashton, president
and CEO of pSivida Corp., will speak at the BioInterface 2015
Annual Symposium of the Surfaces in BioMaterials Foundation being
held September 21-23 in Scottsdale, Arizona. Dr. Ashton will speak
during the Ophthalmic Drug Delivery Session on Tuesday, September
22 and will address “Idea to Product in Ophthalmic Sustained
Release.” Other participants in this session include speakers from
Genentech and Allergan, among others. The session is sponsored by
Ora, Inc.
pSivida’s patented Durasert™ technology, which can deliver drug
for a predetermined period ranging from months to years, is the
basis of three of the only four sustained release products approved
by the FDA to treat back of the eye diseases. The most recent is
ILUVIEN® for diabetic macular edema. Medidur™ for posterior uveitis
is in Phase III clinical trials. These products, which use the same
injectable micro-insert, provide sustained delivery of a
corticosteroid to the back of the eye for three years from a single
injection.
The Surfaces in BioMaterials Foundation is dedicated to
exploring creative solutions to technical challenges at the
BioInterface by fostering education and multidisciplinary
cooperation among industrial, academic, clinical and regulatory
communities. More information on the Foundation is available at
their website: http://www.surfaces.org.
About pSivida Corp.
pSivida Corp. (www.psivida.com), headquartered in Watertown, MA,
is a leader in the development of sustained release, drug delivery
products for treating eye diseases. pSivida has developed three of
only four FDA-approved treatments for back-of-the-eye diseases. The
most recent, ILUVIEN®, a micro-insert for diabetic macular edema,
is licensed to Alimera Sciences and sold in the U.S. and three EU
countries. Retisert®, an implant for posterior uveitis, is licensed
to and sold by Bausch & Lomb. pSivida’s lead product
candidate, Medidur™, a micro-insert for posterior uveitis, is
currently in pivotal phase III clinical trials with an NDA
anticipated as early as the first half of 2017. pSivida’s
preclinical development program is focused on using its core
platform technologies, Durasert™ and/or Tethadur™, to deliver drugs
and biologics to treat wet and dry age-related macular degeneration
(AMD), glaucoma, osteoarthritis and other diseases
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statement Some
of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements include
uncertainties with respect to: actual final IOP safety results for
Medidur Phase III trials; ability to achieve profitable operations
and access to capital; fluctuations in operating results; further
impairment of intangible assets; decline in Retisert royalties;
successful commercialization of, and receipt of revenues from,
ILUVIEN for DME; effect of pricing and reimbursement decisions on
sales of ILUVIEN for DME; consequences of flucinolone acetonide
side effects; number and cost of clinical trials and data necessary
to support an NDA for, approval by Indian regulators of the trial
design for, timing of filing the NDA for, and regulatory approval
and successful commercialization of, Medidur; delays in completion
of clinical trials; increases in cost of clinical trials; changes
in, or misunderstandings with respect to, FDA guidance on required
clinical trials; development of the Latanoprost Product and any
exercise by Pfizer of its option; ability of Tethadur to
successfully deliver large biologic molecules and to develop
products using it; ability to successfully develop product
candidates, complete clinical trials and receive regulatory
approvals; ability to market and sell products; success of current
and future license agreements; termination of license agreements;
effects of competition and other developments affecting sales of
products; market acceptance of products; effects of guidelines,
recommendations and studies; protection of intellectual property
and avoiding intellectual property infringement; retention of key
personnel; product liability; industry consolidation; compliance
with environmental laws; manufacturing risks; risks and costs of
international business operations; legislative or regulatory
changes; volatility of stock price; possible dilution; absence of
dividends; and other factors described in our filings with the SEC.
You should read and interpret any forward-looking statements
together with these risks. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate,
actual results could differ materially from past results and those
anticipated, estimated or projected in the forward-looking
statements. You should bear this in mind as you consider any
forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake
any obligation to publicly update or revise our forward-looking
statements even if experience or future changes makes it clear that
any projected results expressed or implied in such statements will
not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook:
https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog:
http://www.thechairmansblog.com/paul-ashton
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903005314/en/
Martin E. Janis & Company, Inc.Beverly JedynakPresidentT:
312-943-1123M: 773-350-5793bjedynak@janispr.com
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jul 2023 to Jul 2024